Weinberg, Daniel N. http://orcid.org/0000-0002-6718-3724
Rosenbaum, Phillip http://orcid.org/0000-0002-2478-2698
Chen, Xiao
Barrows, Douglas
Horth, Cynthia
Marunde, Matthew R.
Popova, Irina K.
Gillespie, Zachary B. http://orcid.org/0000-0001-6597-0049
Keogh, Michael-Christopher http://orcid.org/0000-0002-2219-8623
Lu, Chao http://orcid.org/0000-0003-0982-8122
Majewski, Jacek http://orcid.org/0000-0003-3572-9558
Allis, C. David http://orcid.org/0000-0001-7589-713X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA196539, F30CA224971, P01CA196539)
St. Jude Children’s Research Hospital
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007739, R44GM116584, R44GM117683)
Damon Runyon Cancer Research Foundation (DFS-28-18)
U.S. Department of Health & Human Services | National Institutes of Health (R00CA212257)
American Association for Cancer Research (Gertrude B. Elion Cancer Research Grant)
McGill University
Article History
Received: 4 April 2020
Accepted: 25 March 2021
First Online: 13 May 2021
Competing interests
: M.R.M., I.K.P., Z.B.G. and M.-C.K. declare competing interests. EpiCypher is a commercial developer and supplier of platforms used in this study: recombinant semisynthetic modified nucleosomes and the dCypher nucleosome binding assay. The remaining authors declare no competing interests.